Compare Global X Copper Miners ETF (COPX) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Viatris Inc — how do they compare? Global X Copper Miners ETF trades at $89.34, while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while Global X Copper Miners ETF pays none. Which is the better fit depends on your goals.
| COPX | VTRS | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $95.70 | $17.86 |
52-Week Low | $46.08 | $9.49 |
Market Cap | — | $18.69B |
Enterprise Value | — | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX, the Global X Copper Miners ETF, trades at $88.03, up 2.25% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF provides exposure to copper mining equities, which are leveraged to copper demand from AI data centers and electrification trends. Recent news highlights institutional accumulation and a buying opportunity after a pullback from 2026 highs.
The outlook is positive due to structural copper demand growth, though mining equities have underperformed copper futures year-to-date. Risks include commodity price volatility and supply bottlenecks. Analyst sentiment is bullish, emphasizing COPX as a pick-and-shovel play on AI infrastructure.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
